Alayoud Ahmed, El Kabbaj Driss, Benyahia Mohammed, Asseraji Mohammed, Zemraoui Nadir
Service of Nephrology, Dialysis and Kidney Transplantation, Military Hospital Avicenne, Marrakech, Morocco.
Iran J Kidney Dis. 2015 Mar;9(2):132-7.
It has been suggested that a dialysate calcium concentration of 1.5 mmol/L is a compromise between bone protection and cardiovascular risk. This study aimed to investigate the effect of reducing dialysate calcium concentration to 1.5 mmol/L on mineral metabolism and hemodynamic parameters.
Dialysate calcium concentration was changed from 1.75 mmol/L to 1.5 mmol/L for 9 months and observed the effects on mineral metabolism and dialysis outcome parameters in 52 hemodialysis patients.
The results at 9 months demonstrated that postdialytic serum calcium level decreased significantly from 109 ± 7 mg/L to 102 ± 6 mg/L, intact parathyroid hormone (PTH) increased from 372 ± 52 pg/mL to 606 ± 80 pg/mL, and the oral alfacalcidol increased from 1.4 ± 0.3 µg/w to 3.3 ± 0.4 µg/w. In patients with low PTH levels, continuous increase of PTH was observed. There were no significant variation in the oral calcium carbonate dose and serum levels of alkaline phosphatase, predialytic calcium, and pre- and postdialytic phosphorus. The ultrafiltration rate and postdialysis systolic blood pressure were significantly lower after reducing the dialysate calcium concentration to 1.5 mmol/L. Intradialytic hypotension and cramps were more frequent with this dialysate calcium concentration.
These findings demonstrated that a decrease in dialysate calcium concentration from 1.75 mmol/L to 1.5 mmol/L improved mineral metabolism by prevention of postdialytic hypercalcemia and releasing oversuppression of PTH, but it was associated with more use of oral alfacalcidol and more hemodynamic impairment.
有人提出,透析液钙浓度为1.5 mmol/L是骨骼保护与心血管风险之间的一种折衷方案。本研究旨在探讨将透析液钙浓度降至1.5 mmol/L对矿物质代谢和血流动力学参数的影响。
将52例血液透析患者的透析液钙浓度从1.75 mmol/L改为1.5 mmol/L,持续9个月,并观察其对矿物质代谢和透析结局参数的影响。
9个月时的结果表明,透析后血清钙水平从109±7 mg/L显著降至102±6 mg/L,全段甲状旁腺激素(PTH)从372±52 pg/mL升至606±80 pg/mL,口服阿法骨化醇从1.4±0.3 μg/周增至3.3±0.4 μg/周。在PTH水平较低的患者中,观察到PTH持续升高。口服碳酸钙剂量以及碱性磷酸酶、透析前钙和透析前后磷的血清水平无显著变化。将透析液钙浓度降至1.5 mmol/L后,超滤率和透析后收缩压显著降低。采用该透析液钙浓度时,透析中低血压和痉挛更为频繁。
这些研究结果表明,将透析液钙浓度从1.75 mmol/L降至1.5 mmol/L可通过预防透析后高钙血症和解除对PTH的过度抑制来改善矿物质代谢,但这与更多地使用口服阿法骨化醇以及更多的血流动力学损害有关。